Stem cell gene therapy for early menopause: 2.5-Year Follow-Up shows promise
NCT ID NCT04675970
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 86 women under 40 with premature ovarian failure (early menopause) who had received a one-time gene therapy using their own stem cells. The goal was to check long-term safety and see if hormone levels and fertility improved over 2.5 years. No new treatment was given during follow-up; researchers measured ovarian function and pregnancy rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREMATURE OVARIAN FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Bio-Stem Cell Rehabilitation
Kharkiv, Ukraine
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could cell-derived vesicles restart the ovaries? a new trial investigates
- Frozen ovary tissue reimplanted to reverse infertility after cancer
- Could a simple blood injection reverse early menopause?
- Can a blood injection reboot ovaries? small trial tests PRP for fertility
- Frozen ovary tissue awakened to restore fertility in women with early menopause
- Stem cell shot into ovaries aims to tame perimenopause symptoms